Prenatal X-ray Exposure and Rhabdomyosarcoma in Children: A Report from the Children's Oncology Group
- 1Division of Epidemiology and Biostatistics, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, 2Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, Columbus, Ohio; 3Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota; and 4University of Nebraska Medical Center, Omaha, Nebraska
- Requests for reprints:
Seymour Grufferman, MSC 10 5550, University of New Mexico, Albuquerque, NM 87131. Phone: 626-241-1513; Fax: 626-445-4334. E-mail: sgrufferman{at}salud.unm.edu
Abstract
The association between antenatal diagnostic X-ray exposure and risk of rhabdomyosarcoma in children was assessed in a national case-control study of 319 rhabdomyosarcoma cases and 319 matched controls. Data were collected by telephone interviews of subjects' parents. Overall, an odds ratio (OR) of 1.9 [95% confidence interval (CI), 1.1-3.4] was found for any X-ray examination of the mother during pregnancy. Risk was greatest for X-ray exposure during the first trimester (OR, 5.7; 95% CI, 1.2-27.8) and was also increased for the third trimester (OR, 2.0; 95% CI, 0.9-4.6), whereas second trimester exposure was not associated with increased risk. A nonsignificant increase in risk was found for any X-rays of the abdomen, pelvis, chest, or back. Increased risk was significantly associated with “other” X-ray exposures (relative risk, 2.9; 95% CI, 1.1-7.7), primarily composed of dental X-rays. The association was strongest between embryonal rhabdomyosarcoma and first trimester exposure (relative risk, 10.5; 95% CI, 1.5-458.4). This observation regarding embryonal rhabdomyosarcoma, and our previous report of an increased frequency of major malformations in rhabdomyosarcoma are compatible with findings from animal studies in which Ptc heterozygous knockout mice exhibited an increased risk of radiation-induced development defects and of spontaneously occurring embryonal rhabdomyosarcoma. (Cancer Epidemiol Biomarkers Prev 2009;18(4):1271–6)
Footnotes
-
Grant support: U.S. National Cancer Institute grants CA21244, CA24507, CA30318, CA30969, CA29139, and CA13539, and in part by the Children's Cancer Research Fund, Minneapolis, MN (S. Ognjanovic).
-
Note: S. Grufferman, F. Ruymann, and H.M. Maurer are members of the Intergroup Rhabdomyosarcoma Study.
-
- Accepted January 28, 2009.
- Received September 2, 2008.
- Revision received December 23, 2008.










